Fisher & Paykel Healthcare (NZE:FPH, ASX:FPH) reported earnings of NZ$0.26 per share for the first half of fiscal 2025, up from NZ$0.184 per share a year earlier, according to a Thursday filing with the Australian and New Zealand bourses.

Analysts polled by Visible Alpha expected EPS of NZ$0.30.

Net profit after tax soared 43% year on year to NZ$153.2 million from NZ$107.3 million. Analysts surveyed by Visible Alpha expected NZ$157.5 million.

Total revenue for the half year ended Sept. 30 climbed 18% to a record NZ$951.2 million from NZ$803.7 million a year earlier. The consensus estimate based on the Visible Alpha poll was NZ$943.9 million.

Chief Executive Lewis Gradon attributed the company's robust results to product introductions and changing clinical practice.

"Early indications are that a relatively high hospital census during the period may have contributed as well, as hospitals returned to more normalized staffing and capacity, and seasonal hospitalizations in the Northern Hemisphere from FY24 persisted into the beginning of our current financial year," Gradon added.

For fiscal 2025, Fisher & Paykel maintained its operating revenue guidance of roughly NZ$1.9 billion to NZ$2 billion and after-tax net profit forecast of NZ$320 million to NZ$370 million. Analysts surveyed by Visible Alpha expect revenue of NZ$2 billion and after-tax net profit of NZ$360 million.

The medical device products manufacturer declared a dividend of NZ$0.185 per share, payable on Dec. 18 to shareholders of record as of Dec. 6. This compares with a dividend of NZ$0.175 per share in the year-earlier period.

The company's shares were down more than 2% in recent Thursday trade in New Zealand.

Price (AUD): $37.63, Change: $-0.79, Percent Change: -2.06%